Literature DB >> 33953460

Usefulness of statins in end-stage renal disease.

Mahmoud Abdelnabi1, Nouran Eshak2, Abdallah Almaghraby3, Yehia Saleh3,4, Fady Gerges5, Ashraf Ahmed3.   

Abstract

End-stage renal disease (ESRD) is considered an independent risk factor of cardiovascular and cerebrovascular events. This review highlights atherosclerotic risk, lipid metabolism alterations, and four studies on the use of statins in ESRD-two of which showed a statistically significant effect of statins on the primary endpoints and two of which did not. Since effects were seen with higher doses of statins, further research is needed on the protective effects of intermediate to higher doses of statins in ESRD patients. Baylor University Medical Center Proceedings.

Entities:  

Keywords:  Cardiovascular mortality; cerebrovascular mortality; end-stage renal disease; statin therapy

Year:  2021        PMID: 33953460      PMCID: PMC8059899          DOI: 10.1080/08998280.2021.1874774

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  11 in total

1.  Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients.

Authors:  M Koch; B Kutkuhn; E Trenkwalder; D Bach; B Grabensee; H Dieplinger; F Kronenberg
Journal:  J Am Soc Nephrol       Date:  1997-12       Impact factor: 10.121

Review 2.  Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.

Authors:  Hudaifa Alani; Asad Tamimi; Nihad Tamimi
Journal:  World J Nephrol       Date:  2014-11-06

3.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

4.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.

Authors:  Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

Review 5.  Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Gladys Block; Michael H Humphreys; Joel D Kopple
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

6.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Authors:  Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

7.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

8.  Dyslipidemia associated with chronic kidney disease.

Authors:  Vasilis Tsimihodimos; Zoi Mitrogianni; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

9.  Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease.

Authors:  Eun Yeong Cho; Chana Myoung; Hong-Suk Park; Ae Jin Kim; Han Ro; Jae Hyun Chang; Hyun Hee Lee; Wookyung Chung; Ji Yong Jung
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

10.  Statins and All-Cause Mortality in Patients Undergoing Hemodialysis.

Authors:  Jaehun Jung; Gi Hwan Bae; Minsun Kang; Soo Wan Kim; Dae Ho Lee
Journal:  J Am Heart Assoc       Date:  2020-02-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.